Nature Medicine, Published online: 10 September 2026; doi:10.1038/s41591-026-04572-7
In a phase 1 trial evaluating intravenous delivery of a next-generation CD3×CD19 bispecific T cell engager in patients with active systemic lupus erythematosus, treatment was well tolerated, and there were improvements in disease activity scores for most patients.
